R
Robin Goland
Researcher at Columbia University
Publications - 130
Citations - 14561
Robin Goland is an academic researcher from Columbia University. The author has contributed to research in topics: Diabetes mellitus & Type 1 diabetes. The author has an hindex of 57, co-authored 122 publications receiving 12849 citations. Previous affiliations of Robin Goland include Columbia University Medical Center.
Papers
More filters
Journal ArticleDOI
Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons.
John T. Dimos,Kit T. Rodolfa,Kathy K. Niakan,Laurin M. Weisenthal,Hiroshi Mitsumoto,Wendy K. Chung,Wendy K. Chung,Gist F. Croft,Genevieve Saphier,Rudy Leibel,Robin Goland,Hynek Wichterle,Christopher E. Henderson,Kevin Eggan +13 more
TL;DR: Induced pluripotent stem cells are generated from an 82-year-old woman diagnosed with a familial form of amyotrophic lateral sclerosis and were successfully directed to differentiate into motor neurons, the cell type destroyed in ALS.
Journal ArticleDOI
Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function
Mark D. Pescovitz,Carla J. Greenbaum,Heidi Krause-Steinrauf,Dorothy J. Becker,Stephen E. Gitelman,Robin Goland,Peter A. Gottlieb,Jennifer B. Marks,Paula McGee,Antoinette Moran,Philip Raskin,Henry Rodriguez,Desmond A. Schatz,Diane K. Wherrett,Darrell M. Wilson,John M. Lachin,Jay S. Skyler +16 more
TL;DR: The finding that B lymphocytes contribute to the pathogenesis of type 1 diabetes may open a new pathway for exploration in the treatment of patients with this condition.
Journal ArticleDOI
Generation of pluripotent stem cells from patients with type 1 diabetes.
René Maehr,Shuibing Chen,Melinda Snitow,Thomas Ludwig,Lisa Yagasaki,Robin Goland,Rudolph L. Leibel,Douglas A. Melton +7 more
TL;DR: It is shown that induced pluripotent stem (iPS) cells can be generated from patients with T1D by reprogramming their adult fibroblasts with three transcription factors (OCT4, SOX2, KLF4).
Journal ArticleDOI
Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial
Tihamer Orban,Brian N. Bundy,Dorothy J. Becker,Linda A. DiMeglio,Stephen E. Gitelman,Robin Goland,Peter A. Gottlieb,Carla J. Greenbaum,Jennifer B. Marks,Roshanak Monzavi,Antoinette Moran,Philip Raskin,Henry Rodriguez,William E. Russell,Desmond A. Schatz,Diane K. Wherrett,Darrell M. Wilson,Jeffrey P. Krischer,Jay S. Skyler +18 more
TL;DR: Abatacept (10 mg/kg, maximum 1000 mg per dose) or placebo infusions intravenously on days 1, 14, 28, and monthly for a total of 27 infusions over 2 years.
Journal ArticleDOI
Evidence of a Strong Association Between Frequency of Self-Monitoring of Blood Glucose and Hemoglobin A1c Levels in T1D Exchange Clinic Registry Participants
Kellee M. Miller,Roy W. Beck,Richard M. Bergenstal,Robin Goland,Michael J. Haller,Janet B. McGill,Henry Rodriguez,Jill H. Simmons,Irl B. Hirsch +8 more
TL;DR: There is a strong association between higher SMBG frequency and lower HbA1c levels, and it is important for insurers to consider that reducing restrictions on the number of test strips provided per month may lead to improved glycemic control for some patients with type 1 diabetes.